Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 5/20 | 0.66 |
| ▸ | CA2 | P00918 | 5/20 | 0.66 |
| ▸ | CA9 | Q16790 | 5/20 | 0.66 |
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11863715 | 0.90 | LMNA (0.69) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL28927348 | 0.88 | LMNA (0.76) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL4860551 | 0.87 | LMNA (0.66) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL7949201 | 0.86 | LMNA (0.68) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL2670090 | 0.85 | LMNA (0.94) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL4091924 | 0.85 | LMNA (0.71) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL2221140 | 0.85 | LMNA (1.00) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL5313560 | 0.85 | LMNA (1.00) | LMNAMAPK1ALDH1A1THRBTSHR | |
| Metronidazole SCHEMBL9482744 | 0.85 | LMNA (1.00) | LMNAMAPK1ALDH1A1THRBTSHR | |
| SCHEMBL11521436 | 0.85 | LMNA (0.71) | LMNAMAPK1ALDH1A1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-05-16 | — | — | US | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-9028799-B2 | Nitroimidazole-amino acid hypoxia contrast medium, preparation method and use thereof | RUAN JIANPING (CN) | 2015-05-12 | — | — | US | disclosed |
| WO-2015025283-A2 | DUAL ACTION CARBONIC ANHYDRASE INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC" (NL) | 2015-02-26 | — | — | WO | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110206604-A1 | NITROIMIDAZOLE-AMINO ACID HYPOXIA CONTRAST MEDIUM, PREPARATION METHOD AND USE THEREOF | RUAN JIANPING | 2011-08-25 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1753512-B1 | TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1756118-B1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2008-05-28 | — | — | EP | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | LMNA 376/4885MAPK1 1250/4885ALDH1A1 3797/4885 |
| US-11649215-B2 | Compositions and methods for the treatment of oral infectious diseases | SI, HBG1, HBG2 | LMNA 1815/4885MAPK1 3699/4885ALDH1A1 3560/4885 |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | LMNA 2408/4885MAPK1 4332/4885ALDH1A1 1589/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | LMNA 350/4885MAPK1 1749/4885ALDH1A1 3599/4885 |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, BAD | LMNA 3889/4885MAPK1 1328/4885ALDH1A1 683/4885 |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | BCL2, BAX, MCL1 | LMNA 3882/4885MAPK1 2300/4885ALDH1A1 317/4885 |
| US-20110206604-A1 | NITROIMIDAZOLE-AMINO ACID HYPOXIA CONTRAST MEDIUM, PREPARATION METHOD AND USE THEREOF | HIF1AN, HIF1A, NUCB2 | LMNA 1372/4885MAPK1 1567/4885ALDH1A1 4686/4885 |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | RB1, BAX, BCL2 | LMNA 3601/4885MAPK1 599/4885ALDH1A1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.